NCT03748641 2026-03-16MAGNITUDEJanssen Research & Development, LLCPhase 3 Active not recruiting765 enrolled 16 charts 1 FDA
NCT04037254 2026-03-16Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of RecurringNRG OncologyPhase 1/2 Completed22 enrolled 13 charts
NCT02655016 2026-03-10A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyTesaro, Inc.Phase 3 Active not recruiting733 enrolled 21 charts 2 FDA
NCT04288687 2026-03-04A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair DefectsAbramson Cancer Center at Penn MedicinePhase 2 Completed11 enrolled 13 charts